Details

Autor(en) / Beteiligte

• Ellert, Julia
• Christiansen, Evald Høj
• Maeng, Michael
• Raungaard, Bent
• Jensen, Svend Eggert
• Kristensen, Steen Dalby
• Veien, Karsten Tange
• Junker, Anders Bo
• Jakobsen, Lars
• Aarøe, Jens
• Terkelsen, Christian Juhl
• Kahlert, Johnny
• Villadsen, Anton Boel
• Bøtker, Hans Erik
• Jensen, Lisette Okkels

Titel

Impact of diabetes on clinical outcomes after revascularization with sirolimus‐eluting and biolimus‐eluting stents with biodegradable polymer from the SORT OUT VII trial

Ist Teil von

• Catheterization and cardiovascular interventions, 2019-03, Vol.93 (4), p.567-573

Ort / Verlag

Hoboken, USA: John Wiley & Sons, Inc

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• Objectives In this substudy of the SORT OUT VII trial, the clinical outcomes among patient with diabetes mellitus treated with Orsiro sirolimus‐eluting stent (O‐SES; Biotronik, Bülach, Switzerland) or Nobori biolimus‐eluting stent (N‐BES; Terumo, Tokyo, Japan) were compared. Background Diabetes is associated with increased risk of target lesion failure (TLF) after percutaneous coronary intervention. Methods In total, 2525 patients were randomized to stent implantation with O‐SES (n = 1261, diabetes: n = 236) or N‐BES (n = 1264, diabetes: n = 235). The primary endpoint, TLF, was a composite of cardiac death, target‐lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 2 years. Results At 2 year, TLF did not differ between O‐SES vs N‐BES in diabetic (9.3% vs 9.4%; RR 0.98, 95% CI 0.54–1.78) patients. The individual components of the primary endpoint did not differ among stent type. In diabetics, cardiac death occurred in 3% of O‐SES‐treated and in 3.8% of N‐BES‐treated patients (RR 0.77, 95% CI 0.29–2.08), MI occurred in 3.0% of O‐SES‐treated and in 3.8% of N‐BES‐treated patients (RR 0.76, 95% CI 0.28–2.06) and TLR occurred in 5,5% of O‐SES‐treated and in 6.0% of N‐BES‐treated patients (RR 0.91, 95% CI 0.43–1.95). Conclusion TLF did not differ between O‐SES‐ and N‐BES‐treated diabetic patients.